But Sutent's benefits may still outweigh its risks for many patients, experts say
WEDNESDAY, Feb. 13 (HealthDay News) -- A greater percentage of patients than previously thought may develop heart failure when taking the breakthrough cancer drug Sutent, researchers report.
The drug was approved for advanced kidney cancer and a rare form of gastrointestinal cancer.
"Our data support a role for routine cardiac monitoring for patients receiving sunitinib [Sutent] and careful study of adverse cardiac events in future studies," said study author Dr. Melinda Telli, a postdoctoral fellow in medical oncology at Stanford University School of Medicine. "This is especially important, because sunitinib is being investigated in over 30 different tumor types for advanced as well as early forms of cancer. Determining what factors put patients at increased risk will allow us to administer this medication more safely for patients whose benefits clearly outweigh the risks."
Telli was to present the findings at the 2008 Genitourinary Cancers Symposium in San Francisco. She spoke to reporters at a Tuesday teleconference.
Other experts agreed that monitoring of patients on Sutent is advisable, but they also cautioned that there is still little reason for alarm.
"This is a small study and one that makes us want to look further into it . . . but this is not a crystal clear characterization of injury," said Dr. Patrick Lowry, an assistant professor of surgery at Texas A&M Health Science Center College of Medicine and section head of laparoscopy and endourology at Scott & White Memorial Hospital in Temple.
"At the same time, this certainly is more patients with heart failure than they saw with the initial studies," Lowry said. "Perhaps, as they suggested, we need to follow patients a little bit closer from a cardiac standpoint."
And, Lowry pointed out, patients being treated with Sutent often
All rights reserved